Wholomics, a startup formed by researchers from Dana Farber and University College London, unveiled early data on its nuclear magnetic resonance–based assay detecting metabolic signatures in serum samples for a broad spectrum of cancers including pancreatic, colorectal, lung, and breast. Their approach focuses on functional metabolic, lipidomic, and lipoproteomic patterns rather than DNA mutation detection, potentially improving sensitivity for early-stage tumors. Validation studies have been presented at ASCO, emphasising applications in pancreatic cancer screening, a notably challenging tumor type.